Historically, metabolic studies in platelets have primarily investigated events occurring during ex vivo platelet storage, less so the consequences of metabolic alterations on platelet homeostasis and physiologic function. The importance of such studies is emphasized by the recent finding of platelet mitochondrial dysfunction in type 2 diabetes, sickle cell disease, and sepsis. [1][2][3][4][5][6][7] These early investigations used radiometric methods with labeled glucose to study glycolysis and oxidative phosphorylation in platelets. 8,9 Recently, these techniques have been supplanted by more sophisticated investigative tools that allow more rapid analysis of small volume samples, including high-resolution respirometry 10,11 and Seahorse extracellular flux analysis. [12][13][14] Glycolysis and oxidative phosphorylation, as well as glutaminolysis and fatty acid b oxidation, all function to support the metabolic demand in platelets. 10,[14][15][16] The metabolic flexibility of the platelet has been emphasized by investigations demonstrating that activated platelets exhibit a glycolytic phenotype while preserving mitochondrial function and can easily switch between glucose and fatty acid catabolism to support activation. 12 The recently published study by A. K. Chauhan's group further advances our understanding of the understudied field of platelet metabolism. 13 In this paper, the authors demonstrate that dichloroacetate, an inhibitor of pyruvate dehydrogenase kinases, alters platelet metabolism and function. 13 Finding salutary antiaggregatory and antithrombotic effects of dichloroacetate, the authors propose targeting of the platelet metabolic response as a novel antithrombotic approach. However, there are few points of clarification we would like to add, which we believe will be of great benefit for the platelet and mitochondria research community in their exploration of this new therapeutic avenue. 13